ArticleOdontology2026
Dexamethasone/β-cyclodextrin inclusion complex hydrogel for vital pulp therapy.
Article in Odontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Targeting inflammation and mineralization responses in a controlled manner for vital pulp therapies is a challenging task. Here, we prepared dexamethasone-β-cyclodextrin (DEX/ICD) inclusion complex-loaded hydrogels for pulp-dentin complex regeneration. The formation of the DEX/ICD inclusion complex was verified using Fourier-transformed infrared spectroscopy (FTIR) and X-ray diffraction (XRD). Pristine dexamethasone (DEX) and DEX/ICD were added to methacrylated gelatin (GelMA) hydrogels at a concentration of 1%. Pristine GelMA serves as the control. Drug-loaded hydrogels were evaluated for mechanical properties (n = 10/group), swelling and enzymatic degradation (n = 5/group), and drug release (n = 3/group). Cell proliferation, cell morphology, and mineralization assays were conducted using SHEDs. Cell proliferation was assessed on days 1, 3, and 7 using the MTS assay (n = 6/group). Cell morphology was analyzed via fluorescence microscopy using phalloidin and DAPI. A mineralization assay was performed using Alizarin Red at 14 and 21 days (n = 4/group). One-way ANOVA and Tukey's (α = 0.05) post-hoc tests were applied for statistical analysis. FTIR and XRD data confirmed the formation of the DEX/ICD complex. No statistical differences were found in mechanical properties, swelling, and degradation after incorporating DEX or DEX/ICD. DEX/ICD-loaded hydrogels consistently released dexamethasone, peaking at day 14, and maintained stability until day 21. DEX-loaded GelMA release decreased after day 7. DEX/ICD-loaded GelMA exhibited higher cell proliferation than DEX-loaded GelMA on day 7 (p < 0.05), with no statistical differences observed for days 1 and 3 (p > 0.05). The hydrogels did not compromise cell morphology. DEX/ICD-loaded GelMA significantly enhanced mineralization potential (p < 0.05). The β-CD inclusion complex optimized dexamethasone delivery, and DEX/ICD-containing GelMA enhances the proliferation and mineralization capacity of dental stem cells. DEX/ICD-loaded GelMA is a promising injectable material for halting inflammation and could potentially induce mineralized tissue formation in pulp capping strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.